AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01883765 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback active
Study NCT03198169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atteris Antimicrobial Barrier Film Dressing
Description: Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
Study NCT03950674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV infusion
Study NCT03950674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT01289457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
Study NCT03950674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT02119091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study NCT00846287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
Study NCT00846287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyperpolarized Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
Study NCT00846287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will inhale a placebo (nebulized saline) with no drug.
Study NCT00846287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aformoterol
Description: Subjects will receive the drug arformoterol prior to scanning
Study NCT04728867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: to compare the educational effectiveness of various educational tools
Description: This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.
Study NCT02692820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
Study NCT02692820 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The placebo contains excipients alone in a gelatin capsule
Study NCT01323673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate 0.05%
Description: 2 times a day, 14 total days study treatment
Study NCT01323673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle / Placebo
Description: 2 times a day, 14 total days of study treatment
Study NCT00366834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) oral tablets
Study NCT00366834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) intravenous
Study NCT01590992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based psychotherapy for somatic symptoms
Description: Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
Study NCT03950674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT03950674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT03950674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT03950674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT03950674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Study NCT01590992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation therapy
Description: Progressive muscle relaxation (Jacobson)
Study NCT01070043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg/Valsartan 80 mg
Description: Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
Study NCT01070043 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks
Study NCT01070043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks
Study NCT02259218 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04368273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: a new treatment drug combined radical radiotherapy concurrent chemotharpy
Study NCT02962154 — intervention group
Intervention type: RADIATION
Intervention: Coronary CT Angiography
Description: The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
Study NCT02962154 — intervention group
Intervention type: OTHER
Intervention: Mood Symptom Scale
Description: Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale
Study NCT02962154 — intervention group
Intervention type: OTHER
Intervention: Anxiety Symptom Scale
Description: Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)
Study NCT02962154 — intervention group
Intervention type: OTHER
Intervention: Chronic Stress Inventories
Description: Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist
Study NCT02962154 — intervention group
Intervention type: OTHER
Intervention: Psychosocial Function Questionnaires
Description: Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)
Study NCT02962154 — intervention group
Intervention type: OTHER
Intervention: General Health and quality of life questionnaires
Description: Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire
Study NCT02962154 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
Study NCT03276819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Samples collection
Description: OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples
Study NCT03276819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and Sociological evaluation
Description: Cohort B ....
Study NCT03276819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive and sustained smoking cessation program
Description: Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)
Study NCT03276819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco and alcohol status follow-up
Description: Evaluation of the tobacco and alcohol status all along the study (questionnaires)
Study NCT00753779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colesevelam HCl tablets, and simvastatin tablets
Description: colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
Study NCT00753779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: simvastatin tablets and colesevelam HCl placebo
Description: simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
Study NCT05337293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE-HF Partnership Intervention
Description: Participants were trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems experienced in the home over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention was to move HF patients toward a positive problem orientation and use of rational problem-solving strategies that support greater HF self-care and reduce depression. The COPE-HF Partnership Intervention consisted of 1 home visit and 7 follow-up telehealth sessions led by a registered nurse interventionist.
Study NCT05337293 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Attention
Description: Participants in the attention group received a sham intervention that consisted of scheduled telephone calls consistent with the timing of that received by the intervention group. During these calls, basic information was gathered on key areas of heart failure self-care management and the frequency of healthcare usage. No intervention or education was provided.
Study NCT01484054 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print and PVP for dark eyes (EAPVPDE)
Description: A daily disposable contact lens
Study NCT03950674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Study NCT01484054 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A control lens (EADE)
Description: A marketed daily disposable contact lens
Study NCT03950674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Study NCT03950674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Study NCT03950674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study NCT00764491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Structural Allograft Spacer
Description: Following disc space preparation the spacer is placed in accordance with cleared labeling and supplemental instrumentation is provided as an adjunct to fixation.
Study NCT01883765 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback sham
Study NCT03950674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study NCT03950674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: IV infusion
Study NCT00709137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
Study NCT00709137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiloride
Description: amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
Study NCT02134639 — intervention group
Intervention type: PROCEDURE
Intervention: 68Ga-DOTATOC PET-CT Imaging
Study NCT00764491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiMesh 1500S
Description: Following disc space preparation the OptiMesh is deployed and filled in accordance with study surgical technique and supplemental instrumentation is provided as an adjunct to fixation.
Study NCT02634281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Study NCT00522223 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times.
Study NCT02445846 — intervention group
Intervention type: DEVICE
Intervention: dual HIV/syphilis rapid diagnostics tests
Study NCT00002923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN5500
Study NCT02634281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Study NCT04439760 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Cervical Ganglion Block
Description: Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
Study NCT01883765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Metacognitive Training
Study NCT03131141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC-3781
Description: Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
Study NCT02244554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
Study NCT02825043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula
Description: This is a humidified oxygen delivery system.
Study NCT03582137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
Study NCT03582137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to this arm will receive Placebo
Study NCT00377598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
Study NCT00377598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
Study NCT00377598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
Study NCT00377598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
Study NCT00377598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
Study NCT00774111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 50 mg in combination with Etravirine
Study NCT00990756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03526299
Description: dry powder for inhalation, 1.396 mg, BID for 14 days
Study NCT00990756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03526299
Description: dry powder for inhalation, 4 mg, BID for 14 days
Study NCT04551157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Viewing
Description: Two patient information videos containing practical advice from staff about the recovery process, images of the wound throughout the healing process and ways to cope with the range of emotional responses that patients report following an open fracture.
Study NCT00955461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RevLite laser treatment
Description: Electro-optic Q-Switched Nd: YAG Laser treatment
Study NCT00955461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser treatment
Study NCT00250224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiotherapy stent
Study NCT00578227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
Study NCT00578227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix ™ Paediatric
Description: Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
Study NCT00578227 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix ™ Paediatric
Description: Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
Study NCT04795102 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: immediate implant placement with ATBG and L-PRF
Description: immediate implant placement using ATBG as a graft material, with L-PRF
Study NCT04795102 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with ATBG
Description: immediate implant placement using ATBG as a graft material without L-PRF